0RPS.LSE Medicover AB Series B
- Market cap
- SEK 27.7B
- P/E
- 465.5x
- P/B
- -
- ROE
- 17.0%
- Dividend yield
- 0.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0RPS.LSE undervalued?
Graham numberThe Graham number of Medicover AB Series B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medicover AB Series B fundamental analysis
No fundamental analysis for Medicover AB Series B yet.
Medicover AB Series B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medicover AB Series B
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hos…
Full company profileMedicover AB Series B financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medicover AB Series B annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 497M | 580M | 672M | 844M | 998M | 1.38B | 1.51B | 1.75B | 2.09B | 2.42B | 2.49B |
| Gross Profit | 120M | 142M | 164M | 207M | 264M | 395M | 340M | 359M | 448M | 561M | 591M |
| Operating Income | 21.1M | 28.8M | 35.5M | 49.7M | 61.3M | 159M | 55.2M | 61.4M | 70.3M | 159M | 194M |
| EBITDA | 43.0M | 52.8M | 91.4M | 123M | 159M | 273M | 223M | 239M | 272M | 378M | 410M |
| Net Income | 4.30M | 18.7M | 22.3M | 22.5M | 25.8M | 102M | 11.8M | 17.6M | 16.7M | 79.0M | 91.6M |
| EPS | 0.04 | 0.16 | 0.17 | 0.17 | 0.18 | 0.69 | 0.08 | 0.12 | 0.11 | 0.52 | 0.60 |
| Balance Sheet | |||||||||||
| Total Assets | 420M | 504M | 728M | 1.02B | 1.11B | 1.68B | 1.83B | 1.94B | 2.14B | 2.41B | 2.44B |
| Total Liabilities | 321M | 200M | 411M | 663M | 627M | 1.12B | 1.32B | 1.41B | 1.65B | 1.87B | 1.89B |
| Shareholders' Equity | 92.7M | 300M | 313M | 317M | 448M | 518M | 472M | 497M | 465M | 531M | 538M |
| Cash & Short-term Investments | 18.4M | 45.4M | 38.4M | 36.4M | 86.8M | 278M | 49.1M | 62.0M | 82.8M | 82.4M | 90.3M |
| Total Debt | 210M | 57.2M | 257M | 452M | 367M | 764M | 940M | 1.00B | 1.24B | 1.91B | 1.47B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.9M | 50.3M | 74.4M | 87.3M | 155M | 2.23B | 1.90B | 205M | 262M | 292M | 227M |
| Capital Expenditure | 45.6M | 29.4M | 41.0M | 63.2M | 72.5M | 1.05B | 1.57B | 111M | 122M | 161M | 110M |
| Free Cash Flow | -19.7M | 20.9M | 33.4M | 24.1M | 82.6M | 1.18B | 331M | 94.5M | 140M | 131M | 117M |
| Ratios | |||||||||||
| ROE | 4.6% | 6.2% | 7.1% | 7.1% | 5.8% | 19.7% | 2.5% | 3.5% | 3.6% | 14.9% | 17.0% |
| ROA | 1.0% | 3.7% | 3.1% | 2.2% | 2.3% | 6.0% | 0.6% | 0.9% | 0.8% | 3.3% | 3.8% |
| Net Profit Margin | 0.9% | 3.2% | 3.3% | 2.7% | 2.6% | 7.4% | 0.8% | 1.0% | 0.8% | 3.3% | 3.7% |
| Debt to Equity | 2.27x | 0.19x | 0.82x | 1.42x | 0.82x | 1.48x | 1.99x | 2.02x | 2.67x | 3.59x | 2.72x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medicover AB Series B dividends
- Dividend yield
- 0.68%
- Forward dividend
- -
- Payout ratio
- 29.0%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 22.9M | 0.15 | 29.0% |
| 2024 | EUR 18.0M | 0.12 | 107.8% |
| 2023 | SEK 17.9M | 0.12 | 101.7% |
| 2022 | SEK 199M | 1.34 | 1,685.3% |
| 2021 | SEK 107M | 0.72 | 105.2% |
| 2020 | SEK 10.4M | 0.07 | 40.3% |
| 2019 | SEK 10.4M | 0.08 | 46.2% |
| 2018 | SEK 10.4M | 0.08 | 46.6% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medicover AB Series B
- Insiders 8.58%
- Institutions 45.45%
- Public & others 45.97%
- Shares outstanding 133M
- Free float 53.1M
Medicover AB Series B company profile
- Company name
- Medicover AB Series B
- Ticker
- 0RPS.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 49,000
- Fiscal year end
- December
- Address
- Riddargatan 12A, Stockholm, Sweden, 102 46
- Phone
- 46 8 40 01 76 00
- Website
- medicover.com
About Medicover AB Series B
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public sector clients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
Medicover AB Series B management
9- Mr. John Paul StubbingtonChief Executive Officer · born 1968
- Mr. Fredrik RagmarkExecutive Officer · born 1963
- Mr. Anand PatelChief Financial Officer · born 1974
- Hanna BjellquistHead of Investor Relations
- Ms. Jenny BrandtGeneral Legal Counsel · born 1974
- Dr. Andrew Vallance-Owen FRCS Ed, MBAChief Marketing Officer · born 1951
- Ms. Kamila SkorupinskiChief People Officer · born 1973
- Mr. Staffan TernstromChief Operating Officer for Diagnostic Services · born 1965
- Mr. Lukasz KrauseChief Digital Information Officer